{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:08:59Z","timestamp":1791328139367,"version":"4.3.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03468-1","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:33:30Z","timestamp":1769247210000},"page":"919-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in and Clinical Experience with Subcutaneous Infusion Pump Therapy for Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"43","author":[{"given":"Valerie","family":"LaRoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennalyn","family":"Mayeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Patzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Whittenhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3359-0871","authenticated-orcid":false,"given":"Melisa","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"3468_CR1","doi-asserted-by":"publisher","first-page":"106336","DOI":"10.1016\/j.rmed.2021.106336","volume":"179","author":"B Stubbe","year":"2021","unstructured":"Stubbe B, Opitz CF, Halank M, Habedank D, Ewert R. Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension\u2014a review of the past, present and future. Respir Med. 2021;179:106336.","journal-title":"Respir Med"},{"issue":"4","key":"3468_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1183\/09031936.00097107","volume":"31","author":"M Gomberg-Maitland","year":"2008","unstructured":"Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31(4):891\u2013901.","journal-title":"Eur Respir J"},{"issue":"5 suppl","key":"3468_CR3","doi-asserted-by":"publisher","first-page":"1A","DOI":"10.1016\/j.amjcard.2012.12.002","volume":"111","author":"AB Waxman","year":"2013","unstructured":"Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol. 2013;111(5 suppl):1A-16A.","journal-title":"Am J Cardiol"},{"issue":"5","key":"3468_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/NAN.0000000000000190","volume":"39","author":"T Stewart","year":"2016","unstructured":"Stewart T. Pulmonary arterial hypertension: a focus on infused prostacyclins. J Infus Nurs. 2016;39(5):315\u201326.","journal-title":"J Infus Nurs"},{"issue":"25","key":"3468_CR5","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMra2000348","volume":"385","author":"PM Hassoun","year":"2021","unstructured":"Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385(25):2361\u201376.","journal-title":"N Engl J Med"},{"issue":"24","key":"3468_CR6","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"3468_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"BW Christman","year":"1992","unstructured":"Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"3468_CR8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.healun.2011.03.011","volume":"30","author":"RL Benza","year":"2011","unstructured":"Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant. 2011;30(9):982\u20139.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"3468_CR9","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.","journal-title":"Eur Respir J"},{"issue":"4","key":"3468_CR10","doi-asserted-by":"publisher","first-page":"2401325","DOI":"10.1183\/13993003.01325-2024","volume":"64","author":"KM Chin","year":"2024","unstructured":"Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.","journal-title":"Eur Respir J"},{"issue":"8","key":"3468_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0025-6196(11)60769-6","volume":"83","author":"MD McGoon","year":"2008","unstructured":"McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923\u201331.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"3468_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.healun.2013.08.010","volume":"32","author":"HW Farber","year":"2013","unstructured":"Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant. 2013;32(11):1114\u201322.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"3468_CR13","doi-asserted-by":"publisher","first-page":"e12455","DOI":"10.1002\/pul2.12455","volume":"14","author":"A Raina","year":"2024","unstructured":"Raina A, Sketch MR, Wu B, Broderick M, Shlobin OA. Congruency between clinician-assessed risk and calculated risk of 1-year mortality in patients with pulmonary arterial hypertension: a retrospective chart review. Pulm Circ. 2024;14(4):e12455.","journal-title":"Pulm Circ"},{"issue":"1","key":"3468_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12890-024-03388-w","volume":"24","author":"A Vaidya","year":"2024","unstructured":"Vaidya A, Sketch MR, Broderick M, Shlobin OA. Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional survey. BMC Pulm Med. 2024;24(1):574.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"3468_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/17476348.2022.2011220","volume":"16","author":"R Ewert","year":"2022","unstructured":"Ewert R, Habedank D, Halank M, Stubbe B, Opitz CF. Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. Expert Rev Respir Med. 2022;16(1):57\u201366.","journal-title":"Expert Rev Respir Med"},{"issue":"7","key":"3468_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","volume":"204","author":"A Boucly","year":"2021","unstructured":"Boucly A, Savale L, Ja\u00efs X, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;204(7):842\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3468_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1164\/rccm.202109-2079PP","volume":"205","author":"CD Vizza","year":"2022","unstructured":"Vizza CD, Lang IM, Badagliacca R, et al. Aggressive afterload lowering to improve the right ventricle: a new target for medical therapy in pulmonary arterial hypertension? Am J Respir Crit Care Med. 2022;205(7):751\u201360.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3468_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","volume":"157","author":"M D\u2019Alto","year":"2020","unstructured":"D\u2019Alto M, Badagliacca R, Argiento P, et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest. 2020;157(2):376\u201383.","journal-title":"Chest"},{"issue":"4","key":"3468_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S2213-2600(24)00425-9","volume":"13","author":"FF Rahaghi","year":"2025","unstructured":"Rahaghi FF, Humbert M, Hoeper MM, et al. Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients. Lancet Respir Med. 2025;13(4):364\u201370.","journal-title":"Lancet Respir Med"},{"key":"3468_CR20","volume-title":"ARTISAN: A novel study of mean pulmonary artery pressure-targeted approach with early and rapid trepostinil therapy to reverse right ventricular remodeling in pulmonary arterial hypertension","author":"RL Benza","year":"2023","unstructured":"Benza RL, Lang IM, Matsubara H, et al. ARTISAN: A novel study of mean pulmonary artery pressure-targeted approach with early and rapid trepostinil therapy to reverse right ventricular remodeling in pulmonary arterial hypertension. New Orleans: Poster presented at ACC Anual Scientific Session & Expo; 2023."},{"issue":"5","key":"3468_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296\u2013301.","journal-title":"N Engl J Med"},{"key":"3468_CR22","unstructured":"Veletri (epoprostenol) [prescribing information]. San Francisco, CA: Actelion Pharmaceuticals; 2012."},{"issue":"2","key":"3468_CR23","doi-asserted-by":"publisher","first-page":"e12063","DOI":"10.1002\/pul2.12063","volume":"12","author":"LA Spikes","year":"2022","unstructured":"Spikes LA, Bajwa AA, Burger CD, et al. BREEZE: open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI\u2122 in patients with pulmonary arterial hypertension. Pulm Circ. 2022;12(2):e12063.","journal-title":"Pulm Circ"},{"issue":"18","key":"3468_CR24","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","volume":"55","author":"VV McLaughlin","year":"2010","unstructured":"McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3468_CR25","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s40262-016-0409-0","volume":"55","author":"P Kumar","year":"2016","unstructured":"Kumar P, Thudium E, Laliberte K, Zaccardelli D, Nelsen A. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. 2016;55(12):1495\u2013505.","journal-title":"Clin Pharmacokinet"},{"key":"3468_CR26","unstructured":"Remodulin (treprostinil). Research Triangle Park, NC: United Therapeutics Corp; 2023."},{"key":"3468_CR27","unstructured":"Orenitram (treprostinil). Research Triangle Park, NC: United Therapeutics Corp; 2023."},{"key":"3468_CR28","unstructured":"TYVASO (treprostinil). Research Triangle Park, NC: United Therapeutics Corp; 2022."},{"key":"3468_CR29","unstructured":"TYVASO DPI. Research Triangle Park, NC: United Therapeutics Corp; 2024."},{"issue":"6","key":"3468_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3468_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ahj.2008.10.029","volume":"157","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009;157(4):625\u201335.","journal-title":"Am Heart J"},{"issue":"1","key":"3468_CR32","doi-asserted-by":"publisher","first-page":"e12016","DOI":"10.1002\/pul2.12016","volume":"12","author":"VP Balasubramanian","year":"2022","unstructured":"Balasubramanian VP, Safdar Z, Sketch MR, et al. Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting. Pulm Circ. 2022;12(1):e12016.","journal-title":"Pulm Circ"},{"issue":"6","key":"3468_CR33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","volume":"129","author":"I Lang","year":"2006","unstructured":"Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129(6):1636\u201343.","journal-title":"Chest"},{"issue":"6","key":"3468_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","volume":"28","author":"RJ Barst","year":"2006","unstructured":"Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195\u2013203.","journal-title":"Eur Respir J"},{"issue":"5","key":"3468_CR35","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1378\/chest.121.5.1561","volume":"121","author":"JL Vachi\u00e9ry","year":"2002","unstructured":"Vachi\u00e9ry JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest. 2002;121(5):1561\u20135.","journal-title":"Chest"},{"key":"3468_CR36","unstructured":"Infusion Pump Improvement Initiative: US Food and Drug Administration; 2017. https:\/\/www.fda.gov\/medical-devices\/infusion-pumps\/infusion-pump-improvement-initiative. Accessed Jan 1 2025."},{"key":"3468_CR37","unstructured":"Remunity User Guide. Research Triangle Park, NC: United Therapeutics Corp.; 2023."},{"key":"3468_CR38","unstructured":"RemunityPRO User Guide. Research Triangle Park, NC: United Therapeutics Corp.; 2025."},{"issue":"4","key":"3468_CR39","doi-asserted-by":"publisher","first-page":"204589402110467","DOI":"10.1177\/20458940211046761","volume":"11","author":"K Morland","year":"2021","unstructured":"Morland K, Raina A, Nails A, Classi P, Etschmaier M, Frantz RP. Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension. Pulm Circ. 2021;11(4):20458940211046760.","journal-title":"Pulm Circ"},{"key":"3468_CR40","unstructured":"United Therapeutics Cares Research Triangle Park, North Carolina 27709: United Therapeutics. https:\/\/unitedtherapeuticscares.com\/. Accessed Feb 21 2025."},{"issue":"10","key":"3468_CR41","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1089\/dia.2019.0509","volume":"22","author":"LH Messer","year":"2020","unstructured":"Messer LH, Tanenbaum ML, Cook PF, et al. Cost, hassle, and on-body experience: barriers to diabetes device use in adolescents and potential intervention targets. Diabetes Technol Ther. 2020;22(10):760\u20137.","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"3468_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000503705","volume":"29","author":"NI Mesbah","year":"2020","unstructured":"Mesbah NI, Taha NA, Rahme ZN, Sukkar FF, Omar DM. Experiences of adults using continuous subcutaneous insulin infusion: a qualitative study. Med Princ Pract. 2020;29(3):255\u201361.","journal-title":"Med Princ Pract"},{"key":"3468_CR43","doi-asserted-by":"publisher","first-page":"A2983","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A2983","volume":"211","author":"JST Mayheux","year":"2025","unstructured":"Mayheux JST, LaRoy V, Reed L, Whittenhall M, Patzlaff N, Wilson M. Expert nurse insights on the future for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2025;211:A2983.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3468_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/2045893217706357","volume":"7","author":"A Sofer","year":"2017","unstructured":"Sofer A, Ryan MJ, Tedford RJ, Wirth JA, Fares WH. A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulm Circ. 2017;7(2):326\u201338.","journal-title":"Pulm Circ"},{"issue":"11","key":"3468_CR45","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.healun.2010.06.013","volume":"29","author":"MA Mathier","year":"2010","unstructured":"Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant. 2010;29(11):1210\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"3468_CR46","unstructured":"Pulmonary Hypertension Association. Information. Support. Hope. 2020. https:\/\/phassociation.org\/. Accessed May\u00a05, 2025."},{"issue":"3","key":"3468_CR47","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/2045893217719250","volume":"7","author":"M Kingman","year":"2017","unstructured":"Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, Lombardi S. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017;7(3):598\u2013608.","journal-title":"Pulm Circ"},{"issue":"6","key":"3468_CR48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/NAN.0b013e31818c09b1","volume":"31","author":"A Doran","year":"2008","unstructured":"Doran A, Harris S, Goetz B. Advances in prostanoid infusion therapy for pulmonary arterial hypertension. J Infus Nurs. 2008;31(6):336\u201345.","journal-title":"J Infus Nurs"},{"issue":"3","key":"3468_CR49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1086\/674304","volume":"3","author":"RJ White","year":"2013","unstructured":"White RJ, Levin Y, Wessman K, Heininger A, Frutiger K. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ. 2013;3(3):611\u201321.","journal-title":"Pulm Circ"},{"issue":"9","key":"3468_CR50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2165\/00003088-200847090-00004","volume":"47","author":"N Skoro-Sajer","year":"2008","unstructured":"Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, Gibbs SJ. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet. 2008;47(9):611\u20138.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3468_CR51","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.healun.2012.02.025","volume":"31","author":"R Sadushi-Koli\u00e7i","year":"2012","unstructured":"Sadushi-Koli\u00e7i R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant. 2012;31(7):735\u201343.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"3468_CR52","doi-asserted-by":"publisher","first-page":"204589402199445","DOI":"10.1177\/2045894021994450","volume":"11","author":"EO Jackson","year":"2021","unstructured":"Jackson EO, Brown A, McSweeney J, Parker C. Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network. Pulm Circ. 2021;11(1):2045894021994450.","journal-title":"Pulm Circ"},{"key":"3468_CR53","doi-asserted-by":"publisher","first-page":"1188083","DOI":"10.3389\/fmed.2023.1188083","volume":"10","author":"J Brewer","year":"2023","unstructured":"Brewer J, Kimber A. Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin\u00ae) site pain: a case report. Front Med (Lausanne). 2023;10:1188083.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3468_CR54","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1183\/09031936.00072709","volume":"35","author":"T Thenappan","year":"2010","unstructured":"Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35(5):1079\u201387.","journal-title":"Eur Respir J"},{"issue":"4","key":"3468_CR55","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.healun.2019.12.013","volume":"39","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transplant. 2020;39(4):300\u20139.","journal-title":"J Heart Lung Transplant"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03468-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03468-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:08:46Z","timestamp":1773824926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03468-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3468"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03468-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Valerie LaRoy serves as an advisory board member and\/or speaker for Bayer, Johnson & Johnson, Merck, and United Therapeutics. Eric Roberts serves as an advisory board member and speaker for Janssen Pharmaceuticals, a consultant, advisory board member, and speaker for United Therapeutics, and a consultant and advisory board member for Merck. Jennalyn Mayeux serves as a consultant and\/or speaker for Gossamer Bio, Johnson & Johnson, Liquidia, Merck, and United Therapeutics. Natalie Patzlaff, Reem Ismail and Kari Roberts are employees of United Therapeutics Corporation. Lori Reed serves as a consultant and\/or speaker for Johnson & Johnson, Merck, and United Therapeutics. Traci Stewart serves as a consultant and\/or speaker for Gossamer Bio, Johnson & Johnson, Merck, Roivant, and United Therapeutics; and serves in a leadership role for the Pulmonary Hypertension Association. Mary Whittenhall serves as an advisory board member for Johnson & Johnson, Merck, United Therapeutics, and Gossamer Bio, and has served on leadership committees for the Pulmonary Hypertension Association. Melisa Wilson is a speaker and advisory board member for United Therapeutics, Johnson & Johnson, Bayer, Merck Co., Liquidia, a consultant and advisory board member for Liquidia and Gossamer, and a consultant for the Pulmonary Hypertension Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}